Cargando…
Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein
Hepatitis C Virus (HCV) infects 200 million individuals worldwide. Although several FDA approved drugs targeting the HCV serine protease and polymerase have shown promising results, there is a need for better drugs that are effective in treating a broader range of HCV genotypes and subtypes without...
Autores principales: | Al Olaby, Reem R., Cocquerel, Laurence, Zemla, Adam, Saas, Laure, Dubuisson, Jean, Vielmetter, Jost, Marcotrigiano, Joseph, Khan, Abdul Ghafoor, Catalan, Felipe Vences, Perryman, Alexander L., Freundlich, Joel S., Forli, Stefano, Levy, Shoshana, Balhorn, Rod, Azzazy, Hassan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214736/ https://www.ncbi.nlm.nih.gov/pubmed/25357246 http://dx.doi.org/10.1371/journal.pone.0111333 |
Ejemplares similares
-
CD81 and Hepatitis C Virus (HCV) Infection
por: Fénéant, Lucie, et al.
Publicado: (2014) -
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
por: Fénéant, Lucie, et al.
Publicado: (2015) -
Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
por: Marín, María Q., et al.
Publicado: (2020) -
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
por: Garbuglia, Anna Rosa, et al.
Publicado: (2014) -
The correlation of HCV RNA and HCV core antigen in different genotypes of HCV
por: Xiang, Yu, et al.
Publicado: (2018)